Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amylou Dueck

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Blood|June 7, 2019
Oral idasanutlin in patients with polycythemia veraJohn Mascarenhas, Min Lu, Heidi Kosiorek, et al.
Journal of Pain and Symptom Management|May 29, 2007
Measuring outcomes in randomized prospective trials in palliative careRichard A Mularski, Kenneth Rosenfeld, Stephen Joel Coons, et al.
American Journal of Surgery|April 17, 2017
Is pelvic sentinel node biopsy necessary for lower extremity and trunk melanomas?Darryl Schuitevoerder, Stanley P L Leong, Jonathan S Zager, et al.
JCO Oncology Practice|April 11, 2025
Implementation of Symptom Monitoring With Electronic Patient-Reported Outcomes: Perspectives and Recommendations From Community Oncology Practices (Alliance AFT-39)Gita N Mody, Antonia V Bennett, Angela M Stover, et al.
Annals of Surgery|July 29, 2024
Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of a Presurgical Toolkit (OPTI-Surg)-Final Results of a Phase III Cluster Randomized Trial (Alliance A231601CD)George J Chang, Heather J Gunn, Anne K Barber, et al.
Cancer|April 12, 2011
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trialRuben A Mesa, Hagop Kantarjian, Ayalew Tefferi, et al.
JAMA Oncology|February 3, 2017
Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid LeukemiaNatalie Ertz-Archambault, Heidi Kosiorek, Gretchen E Taylor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2018
High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)Saranya Chumsri, Jeff Sperinde, Heshan Liu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 5, 2021
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 TrialSamuel Martel, Matteo Lambertini, Dominique Agbor-Tarh, et al.
British Journal of Cancer|March 24, 2020
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization TrialDaniel Eiger, Noam F Pondé, Dominique Agbor-Tarh, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Blood|June 7, 2019
Oral idasanutlin in patients with polycythemia veraJohn Mascarenhas, Min Lu, Heidi Kosiorek, et al.
Journal of Pain and Symptom Management|May 29, 2007
Measuring outcomes in randomized prospective trials in palliative careRichard A Mularski, Kenneth Rosenfeld, Stephen Joel Coons, et al.
American Journal of Surgery|April 17, 2017
Is pelvic sentinel node biopsy necessary for lower extremity and trunk melanomas?Darryl Schuitevoerder, Stanley P L Leong, Jonathan S Zager, et al.
JCO Oncology Practice|April 11, 2025
Implementation of Symptom Monitoring With Electronic Patient-Reported Outcomes: Perspectives and Recommendations From Community Oncology Practices (Alliance AFT-39)Gita N Mody, Antonia V Bennett, Angela M Stover, et al.
Annals of Surgery|July 29, 2024
Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of a Presurgical Toolkit (OPTI-Surg)-Final Results of a Phase III Cluster Randomized Trial (Alliance A231601CD)George J Chang, Heather J Gunn, Anne K Barber, et al.
Cancer|April 12, 2011
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trialRuben A Mesa, Hagop Kantarjian, Ayalew Tefferi, et al.
JAMA Oncology|February 3, 2017
Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid LeukemiaNatalie Ertz-Archambault, Heidi Kosiorek, Gretchen E Taylor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2018
High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)Saranya Chumsri, Jeff Sperinde, Heshan Liu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 5, 2021
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 TrialSamuel Martel, Matteo Lambertini, Dominique Agbor-Tarh, et al.
British Journal of Cancer|March 24, 2020
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization TrialDaniel Eiger, Noam F Pondé, Dominique Agbor-Tarh, et al.
Pageof 5